LXEO
Lexeo Therapeutics, Inc.
3.50$
-2.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | +365.4% | -29.1% | +44.0% | +5.1% | +82.9% | |
| – | +364.8% | -41.4% | +55.3% | +1.5% | +49.4% | |
| – | +362.5% | -43.1% | +57.1% | -71.2% | +79.9% | |
| – | +362.5% | -43.1% | +57.1% | +0.0% | +49.6% | |
| – | +450.7% | +9.1% | -87.5% | +14.6% | -26.8% | |
| – | +967.6% | +92.6% | +20.1% | +32.5% | -26.4% | |
| – | +740.5% | -34.3% | -8.1% | +2.5% | +0.2% | |
| – | +6,806.7% | -12.5% | +41.7% | +69.1% | -24.3% | |
| – | – | – | – | +2.9% | +111.1% | |
| – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +5.9% | +19.3% | +68.8% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.